Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Capricor Therapeutics Inc CAPR

Healthcare Biotechnology
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product... see more

Recent & Breaking News (NDAQ:CAPR)

Capricor Therapeutics Announces $23 Million Registered Direct Offering

GlobeNewswire September 29, 2023

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

GlobeNewswire September 29, 2023

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

GlobeNewswire September 6, 2023

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 7, 2023

Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7

GlobeNewswire August 2, 2023

Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors

GlobeNewswire July 24, 2023

Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors

GlobeNewswire July 13, 2023

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

GlobeNewswire June 30, 2023

Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

GlobeNewswire June 13, 2023

Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire June 7, 2023

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 11, 2023

Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11

GlobeNewswire May 4, 2023

Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX(TM) Platform

GlobeNewswire April 27, 2023

Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

GlobeNewswire March 23, 2023

Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 15, 2023

Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15

GlobeNewswire March 8, 2023

Capricor Therapeutics Receives Clinical Research Forum's 2023 Top Ten Clinical Research Achievement Award

GlobeNewswire March 2, 2023

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan

GlobeNewswire February 16, 2023

Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients

GlobeNewswire January 25, 2023

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program

GlobeNewswire January 19, 2023